Medicaid Managed Care Coverage and Utilization Management of Opioid Use Disorder Treatment
阿片类药物使用障碍治疗的医疗补助管理式医疗覆盖范围和利用管理
基本信息
- 批准号:10441595
- 负责人:
- 金额:$ 66.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventAffectAmericanAttentionAwarenessCOVID-19CaringClinicalContractsDataData SetDiagnosisDropsEmergency department visitEnsureEpidemicFDA approvedFee-for-Service PlansHealthHealth Services AccessibilityHospitalizationImprove AccessInsurance CarriersInvestigationKentuckyLinkManaged CareMedicaidMedicalMethodsMonitorNew YorkOhioOpioidOutcomePatientsPharmaceutical PreparationsPoliciesPopulationPositioning AttributePrevalencePublic HealthRandomizedRecording of previous eventsRegulationResearchSelection BiasSeriesSpecific qualifier valueStructureSubstance Use DisorderTimeVirginiaVulnerable Populationsacute careadverse outcomedesignevidence basefallshealth care service utilizationhealth knowledgeinnovationinsightknowledge baselongitudinal analysismortalityopioid epidemicopioid mortalityopioid overdoseopioid use disorderoverdose deathprior authorizationprogramsrelapse risktreatment effecttreatment servicestrend
项目摘要
PROJECT SUMMARY
As the nation continues to grapple with a rapidly changing epidemic of opioid overdose and mortality, there has
been increasing public attention devoted to expanding access to opioid use disorder (OUD) treatment. While
Medicaid is positioned to be a key policy lever to improve access to OUD treatment and reduce mortality
among vulnerable populations, many state Medicaid programs do not cover the full continuum of OUD
treatment and use utilization management parameters that may restrict access. Moreover, most state Medicaid
programs contract with managed care organizations (MCOs). While over 70% of all Medicaid enrollees
participate in MCO plans, little is known about how these plans cover OUD treatment. To fill this gap in the
scientific evidence, we will conduct the first multi-state study of the effects of Medicaid MCO coverage and
utilization management design on OUD treatment receipt and outcomes. The study will break new ground by
encompassing all MCO plans, across multiple states, for the full continuum of treatment. We also propose to
make use of innovative random auto-assignment methods in two state Medicaid programs. Our specific aims
will include: estimating how state Medicaid program contractual regulations and oversight are associated with
MCO plan level coverage and utilization design; estimating how MCO plans’ coverage and utilization
management design are associated with progression through the Cascade of Care (diagnosis, engagement,
medication initiation, and retention); and estimating how MCO plans’ coverage and utilization management
parameters are associated with opioid-related emergency department visits, hospitalizations, and mortality.
The proposed study will be the first comprehensive investigation of the effects of MCO coverage for OUD
treatment services and medications on treatment receipt and outcomes – evidence without which the care of a
large fraction of the OUD population is compromised. The study will also produce new insight into how states
are regulating and monitoring MCO plan coverage and utilization management design. In the midst of the
deadliest drug epidemic in the nation’s history, evidence regarding the impact of Medicaid MCO coverage for
OUD treatment is urgently needed. This research will equip policymakers with evidence-based guidance on
how to structure MCO contractual arrangements to ensure appropriate and efficient access to OUD treatment.
项目摘要
随着国家继续努力应对阿片类药物过量和死亡率迅速变化的流行病,
越来越多的公众关注扩大阿片类药物使用障碍(OUD)治疗的机会。而
医疗补助被定位为改善OUD治疗和降低死亡率的关键政策杠杆
在弱势群体中,许多州的医疗补助计划并没有覆盖OUD的全部连续性
可能限制访问的治疗和使用利用管理参数。此外,大多数州医疗补助
与管理式护理组织(MCOs)签订合同。而超过70%的医疗补助注册者
尽管参与MCO计划的人很少知道这些计划如何涵盖OUD治疗。为了填补这一空白,
科学证据,我们将进行第一次多州研究的影响,医疗补助MCO覆盖面,
OUD治疗接收和结果的使用管理设计。这项研究将开辟新的领域,
涵盖多个州的所有MCO计划,以实现完整的连续治疗。我们亦建议
在两个州的医疗补助计划中使用创新的随机自动分配方法。我们的具体目标
将包括:估计州医疗补助计划合同规定和监督如何与
MCO计划级覆盖和利用率设计;评估MCO计划的覆盖和利用率
管理设计与通过护理级联(诊断,参与,
药物启动和保留);以及估计MCO计划的覆盖范围和使用管理
参数与阿片类药物相关的急诊就诊、住院和死亡率相关。
拟议的研究将是首次全面调查MCO覆盖对OUD的影响
治疗服务和药物治疗接收和结果-证据,没有它的照顾,
大部分的OUD群体受到损害。这项研究还将产生新的见解,
正在规范和监测MCO计划覆盖范围和利用管理设计。你在这些
美国历史上最致命的毒品流行病,关于医疗补助MCO覆盖范围对
因此,迫切需要进行治疗。这项研究将为决策者提供基于证据的指导,
如何构建MCO合同安排,以确保适当和有效地获得OUD治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christina Marie Andrews其他文献
Christina Marie Andrews的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christina Marie Andrews', 18)}}的其他基金
Medicaid Managed Care Coverage and Utilization Management of Opioid Use Disorder Treatment
阿片类药物使用障碍治疗的医疗补助管理式医疗覆盖范围和利用管理
- 批准号:
10617393 - 财政年份:2021
- 资助金额:
$ 66.01万 - 项目类别:
Medicaid Managed Care Coverage and Utilization Management of Opioid Use Disorder Treatment
阿片类药物使用障碍治疗的医疗补助管理式医疗覆盖范围和利用管理
- 批准号:
10298962 - 财政年份:2021
- 资助金额:
$ 66.01万 - 项目类别:
Gender Differences in Access to Publicly-Funded Substance Abuse Services
获得公共资助的药物滥用服务方面的性别差异
- 批准号:
8198382 - 财政年份:2011
- 资助金额:
$ 66.01万 - 项目类别:
Gender Differences in Access to Publicly-Funded Substance Abuse Services
获得公共资助的药物滥用服务方面的性别差异
- 批准号:
7999298 - 财政年份:2011
- 资助金额:
$ 66.01万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 66.01万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 66.01万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 66.01万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 66.01万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 66.01万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 66.01万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 66.01万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 66.01万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 66.01万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 66.01万 - 项目类别: